Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects.

Shi R, Honczarenko M, Zhang S, Fleener C, Mora J, Lee SK, Wang R, Liu X, Shevell DE, Yang Z, Wang H, Murthy B.

J Clin Pharmacol. 2017 Feb;57(2):161-172. doi: 10.1002/jcph.791. Epub 2016 Aug 23.

2.

Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension.

Bauman DR, Whitehead A, Contino LC, Cui J, Garcia-Calvo M, Gu X, Kevin N, Ma X, Pai LY, Shah K, Shen X, Stribling S, Zokian HJ, Metzger J, Shevell DE, Waddell ST.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3650-3. doi: 10.1016/j.bmcl.2013.03.011. Epub 2013 Mar 22.

PMID:
23659858
3.

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).

Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8132-7. Epub 2005 May 31.

4.

Cell wall alterations in the arabidopsis emb30 mutant.

Shevell DE, Kunkel T, Chua NH.

Plant Cell. 2000 Nov;12(11):2047-60.

5.

Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice.

Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, Chun S, Fletcher D, Card DJ, Lisnock J, Weikel R, Bergstrom JD, Shevell DE, Hermanowski-Vosatka A, Sparrow CP, Chao YS, Rader DJ, Wright SD, Puré E.

J Immunol. 2000 Sep 15;165(6):3430-5.

7.
8.
9.

Resistance to alkylation damage in Escherichia coli: role of the Ada protein in induction of the adaptive response.

Shevell DE, Friedman BM, Walker GC.

Mutat Res. 1990 Nov-Dec;233(1-2):53-72. Review. No abstract available.

PMID:
2233813

Supplemental Content

Loading ...
Support Center